Predicting functional decline in behavioural variant frontotemporal dementia.
Behavioural variant frontotemporal dementia is characterized by a change in comportment. It is associated with considerable functional decline over the course of the illness albeit with sometimes dramatic variability among patients. It is unknown whether any baseline features, or combination of features, could predict rate of functional decline in behavioural variant frontotemporal dementia. The aim of this study was to investigate the effects of different baseline clinical, neuropsychological, neuropsychiatric, genetic and anatomic predictors on the rate of functional decline as measured by the Clinical Dementia Rating Sum of Boxes scale. We identified 86 subjects with behavioural variant frontotemporal dementia that had multiple serial Clinical Dementia Rating Sum of Boxes assessments (mean 4, range 2-18). Atlas-based parcellation was used to generate volumes for specific regions of interest at baseline. Volumes were utilized to classify subjects into different anatomical subtypes using the advanced statistical technique of cluster analysis and were assessed as predictor variables. Composite scores were generated for the neuropsychological domains of executive, language, memory and visuospatial function. Behaviours from the brief questionnaire form of the Neuropsychiatric Inventory were assessed. Linear mixed-effects regression modelling was used to determine which baseline features predict rate of future functional decline. Rates of functional decline differed across the anatomical subtypes of behavioural variant frontotemporal dementia, with faster rates observed in the frontal dominant and frontotemporal subtypes. In addition, subjects with poorer performance on neuropsychological tests of executive, language and visuospatial function, less disinhibition, agitation/aggression and night-time behaviours at presentation, and smaller medial, lateral and orbital frontal lobe volumes showed faster rates of decline. In many instances, the effect of the predictor variables observed across all subjects was also preserved within anatomical subtypes. Furthermore, some of the predictor variables improved our prediction of rate of functional decline after anatomical subtype was taken into account. In particular, age at onset was a highly significant predictor but only after adjusting for subtype. We also found that although some predictor variables, for example gender, Mini-Mental State Examination score, and apathy/indifference, did not affect the rate of functional decline; these variables were associated with the actual Clinical Dementia Rating Sum of Boxes score estimated for any given time-point. These findings suggest that in behavioural variant frontotemporal dementia, rate of functional decline is driven by the combination of anatomical pattern of atrophy, age at onset, and neuropsychiatric characteristics of the subject at baseline.
Department of Neurology (Behavioural Neurology), Mayo Clinic, Rochester, Minnesota 55905, USA. josephs.keith@mayo.edu
Keith A
KA
Josephs
Jennifer L
JL
Whitwell
Stephen D
SD
Weigand
Matthew L
ML
Senjem
Bradley F
BF
Boeve
David S
DS
Knopman
Glenn E
GE
Smith
Robert J
RJ
Ivnik
Clifford R
CR
Jack
Ronald C
RC
Petersen
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D053327:Apolipoprotein E4 / Q000235:genetics; D001284:Atrophy / Q000523:psychology; D018450:Disease Progression; D005260:Female; D005625:Frontal Lobe / Q000473:pathology*; D057180:Frontotemporal Dementia / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000523:psychology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009483:Neuropsychological Tests / Q000706:statistics & numerical data; D000077153:Progranulins; D011569:Psychiatric Status Rating Scales; D016875:tau Proteins / Q000235:genetics
D053327:Apolipoprotein E4; C492314:GRN protein, human; D036341:Intercellular Signaling Peptides and Proteins; C054369:MAPT protein, human; D000077153:Progranulins; D016875:tau Proteins
Neuroimage. 2006 Apr 1;30(2):436-43
16300968
IEEE Trans Med Imaging. 1998 Feb;17(1):87-97
9617910
J Clin Exp Neuropsychol. 1998 Apr;20(2):194-200
9777473
Brain. 2008 Mar;131(Pt 3):665-80
18263627
Neurology. 1998 Dec;51(6):1546-54
9855500
Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):202-7
15592131
Neuroimage. 2008 Feb 1;39(3):1034-40
17988893
Int Psychogeriatr. 1997;9 Suppl 1:173-6; discussion 177-8
9447441
Neurology. 2002 Jun 11;58(11):1615-21
12058088
Arch Neurol. 2008 Feb;65(2):249-55
18268196
Neurology. 2009 May 26;72(21):1843-9
19470967
J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):416-8
8163988
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Neurology. 2010 Feb 23;74(8):666-73
20177120
Aging (Milano). 1996 Dec;8(6):379-85
9061124
Neurology. 2009 Mar 3;72(9):813-20
19255408
Neuroimage. 2002 Jan;15(1):273-89
11771995
Neurology. 2009 Nov 17;73(20):1656-61
19917988
Br J Psychiatry. 1982 Jun;140:566-72
7104545
J Psychosom Res. 1998 Jun;44(6):627-8
9678739
J Magn Reson Imaging. 2008 Apr;27(4):685-91
18302232
Stat Med. 2008 Dec 20;27(29):6137-57
18816511
Hum Mol Genet. 2006 Oct 15;15(20):2988-3001
16950801
Neuroimage. 2007 Apr 15;35(3):998-1003
17350290
Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):98-105
12794387
Ann Neurol. 2008 Jul;64(1):4-14
18668533
Neurology. 2005 Aug 9;65(3):397-403
16087904
Arch Neurol. 2006 Nov;63(11):1627-31
17101833
Brain. 2006 Nov;129(Pt 11):3051-65
17071924
Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):362-7
19255708
Neurology. 2009 Nov 3;73(18):1443-50
19884571
J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):441-5
20360166
Neurology. 2002 Jun 25;58(12):1801-8
12084880
Arch Neurol. 2004 Oct;61(10):1579-84
15477512
Nature. 1998 Jun 18;393(6686):702-5
9641683
Arch Neurol. 1988 Jan;45(1):31-2
3337672
Brain. 2008 Mar;131(Pt 3):721-31
18192287
Epidemiology. 1990 Jan;1(1):43-6
2081237
Brain. 2009 Nov;132(Pt 11):2932-46
19762452
Neuroimage. 2005 Jul 1;26(3):839-51
15955494
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
11001602
Neurology. 2009 Sep 29;73(13):1058-65
19786698
Brain. 2008 Nov;131(Pt 11):2957-68
18829698
Neurodegener Dis. 2009;6(3):106-17
19299900
J Neurol Neurosurg Psychiatry. 2001 Mar;70(3):323-32
11181853